P
Pushkal Garg
Researcher at Alnylam Pharmaceuticals
Publications - 21
Citations - 3297
Pushkal Garg is an academic researcher from Alnylam Pharmaceuticals. The author has contributed to research in topics: Belatacept & Transthyretin. The author has an hindex of 10, co-authored 20 publications receiving 1973 citations. Previous affiliations of Pushkal Garg include Mayo Clinic.
Papers
More filters
Journal ArticleDOI
Patisiran, an RNAi Therapeutic, for Hereditary Transthyretin Amyloidosis
David Adams,Alejandra González-Duarte,William O'Riordan,Chih-Chao Yang,Mitsuharu Ueda,Arnt V. Kristen,Ivailo Tournev,Hartmut Schmidt,Teresa Coelho,John L. Berk,Kon Ping Lin,Giuseppe Vita,Shahram Attarian,Violaine Planté-Bordeneuve,Michelle M. Mezei,Josep M. Campistol,Juan Buades,Thomas H. Brannagan,Byoung Joon Kim,Jeeyoung Oh,Yesim Parman,Yoshiki Sekijima,Philip N. Hawkins,Scott D. Solomon,Michael Polydefkis,Peter J. Dyck,Pritesh Gandhi,Sunita Goyal,Jihong Chen,Andrew Strahs,Saraswathy V. Nochur,Marianne T. Sweetser,Pushkal Garg,Pushkal Garg,Akshay Vaishnaw,Akshay Vaishnaw,Jared Gollob,Ole B. Suhr +37 more
TL;DR: Patisiran improved multiple clinical manifestations of hereditary transthyretin amyloidosis with polyneuropathy and showed an effect on gait speed and modified BMI.
Journal ArticleDOI
Phase 3 Trial of RNAi Therapeutic Givosiran for Acute Intermittent Porphyria
Manisha Balwani,Eliane Sardh,Paolo Ventura,Paula Aguilera Peiró,David C. Rees,Ulrich Stölzel,D. Montgomery Bissell,Herbert L. Bonkovsky,Jerzy Windyga,Karl E. Anderson,Charles J. Parker,Samuel M. Silver,Sioban Keel,Jiaan-Der Wang,Penelope E. Stein,Pauline Harper,Daphne Vassiliou,Bruce Wang,John D. Phillips,Aneta Ivanova,Janneke G. Langendonk,Raili Kauppinen,Elisabeth I. Minder,Yutaka Horie,Craig Penz,Jihong Chen,Shangbin Liu,John J. Ko,Marianne T. Sweetser,Pushkal Garg,Akshay Vaishnaw,Jae B. Kim,Amy Simon,Laurent Gouya,Envision Investigators +34 more
TL;DR: Givosiran led to lower levels of urinary ALA and porphobilinogen, fewer days of hemin use, and better daily scores for pain than placebo, and the increased efficacy was accompanied by a higher frequency of hepatic and renal adverse events.
Journal ArticleDOI
Targeting of Antithrombin in Hemophilia A or B with RNAi Therapy
K. John Pasi,Savita Rangarajan,Pencho Georgiev,Tim Mant,Michael Desmond Creagh,Toshko Lissitchkov,David H. Bevan,Steve Austin,Charles R. M. Hay,Inga Hegemann,Rashid S. Kazmi,Pratima Chowdary,Liana Gercheva-Kyuchukova,Vasily Mamonov,Margarita Timofeeva,Chang-Heok Soh,Pushkal Garg,Akshay Vaishnaw,Akin Akinc,Benny Sørensen,Margaret V. Ragni +20 more
TL;DR: Once‐monthly subcutaneous administration of fitusiran resulted in dose‐dependent lowering of the antithrombin level and increased thrombin generation in participants with hemophilia A or B who did not have inhibitory alloantibodies.
Journal ArticleDOI
Effects of Patisiran, an RNA Interference Therapeutic, on Cardiac Parameters in Patients With Hereditary Transthyretin-Mediated Amyloidosis
Scott D. Solomon,David Adams,Arnt V. Kristen,Martha Grogan,Alejandra González-Duarte,Mathew S. Maurer,Giampaolo Merlini,Thibaud Damy,Michel Slama,Thomas H. Brannagan,Angela Dispenzieri,John L. Berk,Amil M. Shah,Pushkal Garg,Akshay Vaishnaw,Verena Karsten,Jihong Chen,Jared Gollob,John Vest,Ole B. Suhr +19 more
TL;DR: The APOLLO study assessed the effect of hereditary transthyretin-mediated (hATTR) amyloidosis on cardiomyopathy or polyneuropathy as mentioned in this paper.
Journal ArticleDOI
Lumasiran, an RNAi Therapeutic for Primary Hyperoxaluria Type 1
Sander F. Garrelfs,Yaacov Frishberg,Sally A. Hulton,Michael J. Koren,William O'Riordan,Pierre Cochat,Georges Deschênes,Hadas Shasha-Lavsky,Jeffrey M. Saland,William van’t Hoff,Daniel Guido Fuster,Daniella Magen,Shabbir H. Moochhala,Gesa Schalk,Eva Simkova,Jaap W. Groothoff,David J. Sas,Kristin Meliambro,Jiandong Lu,Marianne T. Sweetser,Pushkal Garg,Akshay Vaishnaw,John M. Gansner,Tracy L. McGregor,John C. Lieske +24 more
TL;DR: The primary hyperoxaluria type 1 (PH1) is a rare genetic disease caused by hepatic overproduction of oxalate that leads to kidney stones, nephrocalcinosis, kidney failure, and syste....